1.125USD-7.75%Mkt Cap: 127.45M USDP/E: —Last update: 2026-05-26
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to pr…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap127.45M USD
Enterprise Value118.54M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-20.85M USD
Revenue/Share—
Last Price1.125 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees5
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.76
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B96.36
EPS (TTM)-12.70
EPS (Forward)-1.39
52W Range
0.92001% of range19.91
52W High19.91 USD
52W Low0.9200 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-661.54%
ROA-223.94%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-14.82M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-8.32%
Net Debt-1.50M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.00
Current Ratio2.34
Quick Ratio1.60
Book Value/Sh0.0110 USD
Cash/Share0.0130 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateOct 30, 2020
Splits
Last Split1:28
Split DateJun 27, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.113.24M
Float—
Insiders0.74%
Institutions0.07%
Short Interest
Short Ratio1.0d
Short % Float11.16%
Short % Out.3.14%
Shares Short70.40K
Short (prev mo.)13.32K
Technical
SMA 502.125 (-47.0%)
SMA 2002.956 (-61.9%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)85.78K
Avg Vol (10d)109.93K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—